4 Reasons to Buy Medtronic Stock Like There's No Tomorrow

Medtronic’s fiscal 2026 revenue grew 8.4% (+5.8% organic) to $36.4B, its fastest top-line growth in a decade, led by 9.3% organic expansion in cardiovascular devices (+38%+ of enterprise revenue). Free cash flow rose 4.6% to $5.43B, with only $3.64B used for dividends, supporting continued payout growth; the stock yields 3.1% and has raised its dividend for 49 consecutive years. Valuation also looks cheaper, trading at 18x forward earnings vs 21x for peers/S&P 500, with analysts projecting ~14% EPS CAGR (FY26–FY29).

Analysis

The market is likely to treat this as validation rather than a true re-rating event. The key mechanism is that sustained mid/high-single-digit organic growth in a historically slow compounder can narrow the valuation gap versus better-regarded medtech names, but only if the next 2-4 quarters confirm that the cardiovascular mix shift is durable. At ~18x forward earnings, MDT has enough room for a modest rerate, but not enough to absorb any reversion in growth without giving back the multiple.

Competitive dynamics are nuanced: a stronger MDT can pressure pricing in cardiology and structural heart, yet it also signals that the end market is healthy enough to support multiple winners. BSX is the cleanest read-through on whether this is broad category expansion or share recapture; if BSX also reports resilient demand, the entire medtech complex can de-risk. For credit holders, improving free cash flow should tighten spreads and make the debt more attractive than the equity if rates stay elevated, because dividend support reduces left-tail risk more than it creates upside convexity.

Time horizon matters. Over days, this is mostly a slow-grind quality bid; over 1-3 months, the real catalyst is whether guidance and quarterly prints validate the acceleration; over 6-18 months, the dividend-king milestone and cash conversion can support a lower-vol multiple expansion. The thesis is falsified if organic growth falls back below ~6% or free cash flow stops covering dividend growth comfortably. Consensus may be missing that 'cheap' healthcare often stays cheap unless the acceleration proves sticky; this is a quality compounder setup, not a momentum breakout.

Key Decisions for Investors

• Initiate a modest long MDT on pullbacks over the next 1-3 weeks; target 6-12 months, with a thesis break if organic growth drops below 6% or FY27 guidance is cut.
• Pair trade: long MDT / short IHI for 1-3 months to isolate company-specific re-rating versus the broader medtech basket; target 5-8% relative outperformance if cardiovascular growth holds.
• Prefer MDT credit over equity if spreads widen: the improving FCF/dividend coverage makes the bonds a lower-vol way to express the same balance-sheet improvement over 6-18 months.
• Watch BSX and SYK into the next earnings cycle as confirmation trades; if they print similar cardiovascular strength, add to MDT on any post-earnings weakness, but if they show share loss, cap the position.